Navigating new territory in targeted oncology

Ikena is redefining the targeted oncology landscape and envisioning a world in which every cancer patient has a cure, guided by a deep understanding of the patient experience and what drives disease.

Our Focus

We develop therapies that have potential as single agents and in combination to directly target underlying mechanisms driving cancer survival and growth. Our approach enables us to evolve and follow a path guided by translational approaches. See our unique process below.

A Multifaceted Approach

1. Analyze cancer-driving targets in patients with significant therapeutic needs
We employ our insight and a wide array of technologies to identify genetic and signaling dependencies that enable cancer initiation, progression, metastasis, and therapeutic resistance. We are unconstrained to any single platform or method.
2. Identify patients that have specific cancer-driving targets
We leverage a diversity of translational approaches to identify patients that have cancer-driving mutations. We respond with flexibility and creativity to a growing body of data based on an array of biological markers, including creating novel assays as companions to our development candidates.
3. Employ tailored combination of capabilities to discover and develop therapies that target key drivers of cancer progression
Using a fit-for-purpose approach, we leverage our deep expertise in medicinal and computational chemistry and structural biology. With a platform-agnostic strategy, we let the biology determine the technologies we use to discover and develop clinical candidates.
4. Advance therapies that are guided by the patient–our North Star–from beginning to end
Our expertise, diverse processes, and dedication to evolving with science enable us to generate robust data and expand the toolbox of targeted therapies. Through this process, we are closer to achieving our mission of shifting the oncology treatment paradigm to a personalized, biology-driven approach for physicians and their patients.
Previous
Next

Pipeline

We are advancing a diverse array of therapies targeting cancer’s underlying drivers through clinical development.

TARGET ONCOLOGY Program Target Indication Discovery Ind Enabling Phase 1 Late-StageDevelopment IK-930 TEAD Hippo-mutated cancers ERK5 KRAS-mutated cancers Multiple RAS Pathway Targets Multiple Solid tumors TUMOR MICROENVIRONMENT AHR Bladder Cancer IK-412 Kynurenine Multiple Solid Tumors IK-007 + Pembrolizumab 2 EP4 MSS-CRC Phase 1/1b Phase 1/1b Rights & Partnerships 3 BMS 3 BMS 2 IK-175 + Nivo 4
Program Target Indication Discovery IND Enabling Phase 1 Late-Stage Development IK-930 TEAD Hippo-mutated cancers Multiple RAS Pathway Targets; Including ERK5 RAS-mutated cancers Bladder Cancer Additional Tumor Types IK-412 Kynurenine Multiple Solid Tumors IK-007 + Pembro EP4 MSS-CRC AHR IK-175 + Nivo BMS BMS
  1. Ikena has a worldwide exclusive license except China and Taiwan from AskAt.
  2. Pembrolizumab provided through a clinical trial collaboration and supply agreement with Merck.
  3. BMS has the right to exclusively license under a master collaboration agreement.
  4. Nivolumab provided through a clinical trial collaboration and supply agreement with BMS.
Ikena logo left

We are ever-evolving

Visit our site in the near future for a deeper look at our team, our approach and our pipeline of oncology therapies.

Ikena logo right

Team

At Ikena, we strive to see, know, and understand what drives every patient’s cancer so we can make an impact at its root. Every member of our team has something important to contribute to this goal.

Management Team

Mark Manfredi, Ph.D.

Mark Manfredi, Ph.D.

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Douglas R. Carlson

Douglas R. Carlson

Chief Operating Officer & EVP, Finance

Jeffrey Ecsedy, Ph.D.

Jeffrey Ecsedy, Ph.D.

CHIEF SCIENTIFIC OFFICER

Maude Tessier, Ph.D.

Maude Tessier, Ph.D.

CHIEF BUSINESS OFFICER

Alfredo Castro, Ph.D.

Alfredo Castro, Ph.D.

SENIOR Vice President, DISCOVERY

Alexander Constan, Ph.D.

Alexander Constan, Ph.D.

SENIOR Vice President, NON CLINICAL SAFETY AND DMPK

Michelle Zhang, Ph.D.

Michelle Zhang, Ph.D.

SENIOR Vice President, TRANSLATIONAL RESEARCH AND EARLY DEVELOPMENT

Karen McGovern, Ph.D.

Karen McGovern, Ph.D.

Vice President, R&D Collaborations

James Nolan, M.S., MBA

James Nolan, M.S., MBA

Vice President, THERAPEUTICS DEVELOPMENT & MANUFACTURING

Ikena team placeholder

Karim S. Malek, M.D.

Vice President, Clinical Development

Ikena team placeholder

Jennifer Schroeder, PMP

Senior Vice President, Clinical Development Operations

Board of Directors

Mark Manfredi, Ph.D.

President, chief executive officer and director

Scientific Advisory Board

Do you envision a world in which every cancer patient has a cure?

If you’re passionate about advancing cutting edge therapies for cancer patients, join our team.

Contact Us

At Ikena, we’re excited about our work and passionate about our mission.

Please get in touch to learn more:
info@ikenaoncology.com

Interested in partnering with us? Please contact: BD@ikenaoncology.com

Scroll to Top